CN113456636A - Application of flufenidone in preparation of acute liver injury medicine - Google Patents
Application of flufenidone in preparation of acute liver injury medicine Download PDFInfo
- Publication number
- CN113456636A CN113456636A CN202110777586.2A CN202110777586A CN113456636A CN 113456636 A CN113456636 A CN 113456636A CN 202110777586 A CN202110777586 A CN 202110777586A CN 113456636 A CN113456636 A CN 113456636A
- Authority
- CN
- China
- Prior art keywords
- flufenidone
- liver injury
- acute liver
- group
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of flufenidone in preparing a drug for treating acute liver injury, wherein the flufenidone is used as a raw material for preparing the drug for treating acute liver injury, or the drug comprises a flufenidone component. The invention discovers that the flufenidone has the characteristic of treating acute liver injury, so that the application of the flufenidone in preparing the acute liver injury medicament provides a new medicament for treating the acute liver injury, and has better market value and clinical application prospect.
Description
Technical Field
The invention relates to the field of medicines, and in particular relates to application of flufenidone in preparation of a medicine for treating acute liver injury.
Background
Acute Liver Injury (ALI) is a Liver Injury caused by various causes, and its condition progresses rapidly. Studies have shown that exogenous substances, such as viral infections, abuse of alcohol or drugs, and exposure to toxins, can lead to ALI. The first cause of acute liver injury in China is virus infection, and the second cause is medicine. Because chronic liver injury can cause chronic liver inflammation and fibrosis reaction, the necrotizing cirrhosis caused by ALI is not cured. This not only seriously affects the quality of life of the patient, but also imposes a heavy medical burden on the country. Prevention of acute, chronic plus acute and/or chronic liver injury is therefore of great importance to public health. Liver transplantation is one of the most effective treatments for severe ALI, but statistics indicate that fewer than 10% of patients receiving liver transplantation therapy. At present, the treatment of acute liver failure at home and abroad is very limited, and the death rate is very high. Therefore, finding alternative therapies for ALI is an urgent medical need.
A great deal of research has been carried out worldwide to find effective drugs for the prevention and treatment of ALI, some of which have been used clinically for a long time, but the therapeutic effects of these drugs are still unsatisfactory.
Disclosure of Invention
The invention provides application of flufenidone in preparation of an acute liver injury medicament, which is used for solving the technical problem of deficiency of the existing medical field in the treatment of acute liver injury medicaments.
In order to solve the technical problems, the invention adopts the following technical scheme:
an application of flufenidone in preparing the medicine for treating acute liver injury, wherein the flufenidone is used as raw material for preparing the medicine for treating acute liver injury, or the medicine contains flufenidone component.
The flufenidone is 1- (3-fluorophenyl) -5-methyl-2- (1H) pyridone.
Acute liver injury is manifested by rapid loss and abnormality of hepatocyte function, necrosis and apoptosis of a large number of hepatocytes in liver tissue in patients with or without liver disease.
When the flufenidone is used for treating acute liver injury, the administration dosage is 11-55 mg/kg.
Compared with the prior art, the invention has the advantages that:
the invention discovers that the flufenidone has the characteristic of treating acute liver injury, so that the application of the flufenidone in preparing the acute liver injury medicament provides a new medicament for treating the acute liver injury, and has better market value and clinical application prospect.
Drawings
FIG. 1 is a (200-fold) HE staining pattern of liver of each group of mice in a model of acetaminophen-induced acute liver injury;
FIG. 2 is a graph (200-fold) showing HE staining of liver of each group of mice in a lipopolysaccharide/D-galactosamine induced acute liver injury model.
Detailed Description
The invention is described in further detail below with reference to the figures and specific examples.
Example 1:
in this example, flufenidone is applied to the preparation of drugs for acute liver injury, and the therapeutic effect of flufenidone is demonstrated below:
1. experimental methods
(1) Preparing an acetaminophen (APAP) induced Acute Liver Injury (ALI) experimental animal model to observe the curative effect of the flufenidone on the ALI:
SPF grade C57BL/6 mice (7-8 weeks old, male, 20-22g in weight) were prepared and divided into 6 groups, namely a control group, a model group and an experimental group, wherein the experimental group is further divided into the following groups according to the dosage of flufenidone: the flufenidone is 100mg/kg, 150mg/kg, 200mg/kg and 250mg/kg, and each group comprises 5, 9, 5 and 9 respectively. Normal saline or flufenidone with different dosages is administered by intragastric administration half an hour before the molding. Injecting 0.3ml of normal saline into the abdominal cavity of each mouse in the control group; model group and flufenidone-treated mice were injected intraperitoneally with APAP at a dose of 300 mg/kg. Mice were anesthetized 6h after intraperitoneal injection molding and blood was collected to leave serum, followed by sacrifice of the mice.
(2) Preparing an experimental animal model of lipopolysaccharide/D-galactosamine (LPS/D-GaIN) for inducing Acute Liver Injury (ALI) to observe the curative effect of the flufenidone on the ALI:
SPF grade C57BL/6 mice (8-10 weeks old, male, 25-28g weight) were divided into 4 groups, control, model and experimental groups, and the experimental group was further divided according to the dose of flufenidone: and the flufenidone is 250/kg and 500mg/kg, and each group comprises 5, 10, 7 and 7 respectively. Normal saline or flufenidone with different dosages is administered by intragastric administration half an hour before the molding. Injecting 0.3ml of normal saline into the abdominal cavity of each mouse in the control group; model group and flufenidone-treated mice were molded by intraperitoneal injection at a dose of 100. mu.g/kg LPS and 700mg/kg D-GaIN. Mice were anesthetized 6h after intraperitoneal injection molding and blood was collected to leave serum, followed by sacrifice of the mice.
And (3) separating the mouse livers of the step (1) and the step (2), reserving the left outer leaf for preparing a paraffin section, and placing the remaining liver tissue in a liquid nitrogen tank. Liver functions of mice in each group are detected by a continuous monitoring method, and the liver damage condition is observed by HE staining of paraffin sections.
The liver tissue damage scoring standard in the APAP model refers to a method adopted by Zhang-Xu Liu and the like to carry out semi-quantitative analysis on the pathological damage of the liver. Grading standard: 0 minute: no damage is caused; 0.5 min: a single necrotic cell was seen on the first cell layer adjacent to the central layer, and there was subline degeneration; 1 minute: necrotic cells extend from the central vein in two to three cell layers; and 2, dividing: necrotic cells extend from the central vein in three to six cell layers, but are limited to being distributed circumferentially; and 3, dividing: same as 2, but necrosis extends from one central vein to the other; and 4, dividing: more severe than 3, the entire section necrosed extensively in the center of the leaflet. The evaluation standard of the liver tissue damage in the LPS/D-GaIN model refers to CARLOS A. and the like, and the semi-quantitative analysis is carried out on the pathological damage of the liver by the method adopted by the people. Grading standard: level 0: little or no evidence of injury; level 1: mild injury, vacuolation of the cytoplasm, focal nuclear compaction; and 2, stage: moderate to severe injury with extensive nuclear compaction, cytoplasmic eosinophilia, and loss of intercellular borders; and 3, level: with severe necrosis of the liver with loss of liver cords, hemorrhage and neutrophil infiltration. Each section was scored by randomly selecting 5 fields of 200 x field, and the average was the sample score value for this example.
2. The statistical method comprises the following steps: all the measurement data are as follows
The inter-group comparisons were analyzed using one-way variance (ANOVA): the statistical method is a drug field experimentThe most common method for comparing the difference in therapeutic effect among such groups. After differences between groups were obtained, Turky test was used to further verify the differences within the groups, i.e. whether the differences between the model group and the control group and the differences between the dose-administered groups relative to the model group were statistically significant. Definition of two sides p<0.05 was considered statistically significant.
3. Results of the experiment
3.1HE staining results
6 hours after APAP injury, the mouse liver showed extensive nuclear compaction, loss of intercellular borders, loss of hepatic cords and necrosis. In mice treated with flufenidone, the lesions were significantly reduced, lesion coverage was reduced (as shown in figure 1), and the liver lesion pathology score was significantly reduced (p <0.05) compared to the model group, as detailed in tables 1-1. The liver of the mouse has wide intercellular boundary deletion, hepatic cord loss and necrosis, and hepatic sinus congestion 6 hours after the LPS/G-GaIN injury. In mice livers treated with flufenidone, the lesions were significantly reduced, lesion coverage was reduced (as shown in figure 2), and the liver lesion pathology score was significantly reduced (p <0.05) compared to the model group, as detailed in tables 1-2.
Table 1-1. evaluation of liver injury in groups of mice with liver injury due to APAP
In the table, p is compared with the control group<0.05; comparison with control group, p<0.01; comparison with control group, p<0.001；#In comparison with model group, p<0.05；##In comparison with model group, p<0.01；###Compared with the model group, p is less than 0.001.
TABLE 1-2 score of liver injury in groups of mice with LPS/D-GalN induced liver injury
In the table, p is compared with the control group<0.05; comparison with control group, p<0.01; comparison with control group, p<0.001；#In comparison with model group, p<0.05；##In comparison with model group, p<0.01；###Compared with the model group, p is less than 0.001.
3.2 measurement results of blood transaminases of mice in each group
Compared with a control group, the average value of the blood transaminase of the APAP model group mouse is obviously increased compared with that of a normal group mouse, and the difference has statistical significance (p is less than 0.05); after the flufenidone treatment, the blood transaminase of mice is obviously reduced, wherein the treatment effect is best when the dosage is 250mg/kg, and the difference has statistical significance (p is less than 0.001), and the detailed table is shown in table 2-1. The mean value of the blood transaminase of mice in the LPS/D-GalN model group is obviously higher than that of the mice in the normal group, and the difference has statistical significance (p is less than 0.001); after the flufenidone treatment, the blood transaminases of the mice are obviously reduced, wherein the treatment effect is best when the dosage is 500mg/kg, and the difference has statistical significance (p is less than 0.001), which is shown in a table 2-2.
TABLE 2-1 serum transaminase levels in APAP-induced liver injury in various groups of mice
In the table, p is compared with the control group<0.05; comparison with control group, p<0.01; comparison with control group, p<0.001；#In comparison with model group, p<0.05；##In comparison with model group, p<0.01；###Compared with the model group, p is less than 0.001.
TABLE 2-2 serum transaminase levels in various groups of mice with liver damage induced by LPS/D-GalN
In the table, p is compared with the control group<0.05; comparison with control group, p<0.01; comparison with control group, p<0.001；#In comparison with model group, p<0.05；##In comparison with model group, p<0.01；###Compared with the model group, p is less than 0.001.
4. And (4) experimental conclusion: flufenidone can effectively treat acute liver injury of mice induced by APAP and LPS/D-GaIN.
The above description is only a preferred embodiment of the present invention, and the protection scope of the present invention is not limited to the above-described embodiments. Modifications and variations that may occur to those skilled in the art without departing from the spirit and scope of the invention are to be considered as within the scope of the invention.
Claims (4)
1. An application of flufenidone in preparing a drug for treating acute liver injury is characterized in that the flufenidone is used as a raw material for preparing the drug for treating acute liver injury, or the drug comprises a flufenidone component.
2. The use of flufenidone in the preparation of a medicament for treating acute liver injury as claimed in claim 1, wherein the dose of flufenidone administered to a human is from 11 mg/kg to 55 mg/kg.
3. The use of flufenidone in the manufacture of a medicament for treating acute liver injury as recited in claim 1, wherein the flufenidone is 1- (3-fluorophenyl) -5-methyl-2- (1H) pyridone.
4. Use of flufenidone according to claim 1 in the manufacture of a medicament for the treatment of acute liver injury characterized by rapid loss and abnormality of hepatocyte function, massive hepatocyte necrosis and apoptosis in liver tissue in patients with or without liver disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110777586.2A CN113456636A (en) | 2021-07-09 | 2021-07-09 | Application of flufenidone in preparation of acute liver injury medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110777586.2A CN113456636A (en) | 2021-07-09 | 2021-07-09 | Application of flufenidone in preparation of acute liver injury medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113456636A true CN113456636A (en) | 2021-10-01 |
Family
ID=77879478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110777586.2A Pending CN113456636A (en) | 2021-07-09 | 2021-07-09 | Application of flufenidone in preparation of acute liver injury medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113456636A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1846699A (en) * | 2005-04-13 | 2006-10-18 | 中南大学湘雅医院 | Application of 1-(substituted phenyl)-5-methyl-2-(1H)-pyridone compound in preparing medicine for anti-other organifibrosis and tissue fibrosis except renal interstitial fibrosis |
| CN101472588A (en) * | 2007-04-27 | 2009-07-01 | 达瑞科技投资有限公司 | Application of 5-methyl 1-(substituted phenyl group)-2-(1H) pyridinone compound as anti-inflammatory medicament and alpha-tumor necrosis factor (TNF-alpha) |
| WO2009111947A1 (en) * | 2008-03-10 | 2009-09-17 | 广东东阳关药业有限公司 | Crystalline 1-(3-fluorophenyl)-5-methyl-2-(1h)pyridone, the preparation methods, compositions and applications thereof |
| CN101953836A (en) * | 2010-08-13 | 2011-01-26 | 中南大学 | Application of fluoropirfenidone in preparing medicaments for treating psoriasis |
| CN108283639A (en) * | 2018-05-03 | 2018-07-17 | 中南大学 | Fluorofenidone is preparing the application in treating acute kidney injury drug |
-
2021
- 2021-07-09 CN CN202110777586.2A patent/CN113456636A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1846699A (en) * | 2005-04-13 | 2006-10-18 | 中南大学湘雅医院 | Application of 1-(substituted phenyl)-5-methyl-2-(1H)-pyridone compound in preparing medicine for anti-other organifibrosis and tissue fibrosis except renal interstitial fibrosis |
| CN101472588A (en) * | 2007-04-27 | 2009-07-01 | 达瑞科技投资有限公司 | Application of 5-methyl 1-(substituted phenyl group)-2-(1H) pyridinone compound as anti-inflammatory medicament and alpha-tumor necrosis factor (TNF-alpha) |
| WO2009111947A1 (en) * | 2008-03-10 | 2009-09-17 | 广东东阳关药业有限公司 | Crystalline 1-(3-fluorophenyl)-5-methyl-2-(1h)pyridone, the preparation methods, compositions and applications thereof |
| CN101953836A (en) * | 2010-08-13 | 2011-01-26 | 中南大学 | Application of fluoropirfenidone in preparing medicaments for treating psoriasis |
| CN108283639A (en) * | 2018-05-03 | 2018-07-17 | 中南大学 | Fluorofenidone is preparing the application in treating acute kidney injury drug |
Non-Patent Citations (3)
| Title |
|---|
| PENG Y，等: "\"The antihepatic fibrotic effects of fluorofenidone via MAPK signalling pathways\"", 《EUROPEAN JOURNAL OF CLINICAL INVESTIGATION》, vol. 2019, no. 4, pages 358 - 368, XP071217553, DOI: 10.1111/eci.12053 * |
| TU S，等: ""Fluorofenidone protects liver against inflammation and fibrosis by blocking the activation of NF-kappa B pathway"", 《FASEB JOURNAL》, vol. 35, no. 1, pages 2 - 3 * |
| 季嫔嫔，等: ""NF-κB信号通路与急性肝损伤相关性的研究进展"", 《中国民族民间医药》, vol. 2009, no. 17, pages 123 - 124 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101484167A (en) | The use of derviate of pyridone for preventing and treating radioactive injury of lungs | |
| KR101549944B1 (en) | Composition for treating and preventing overavtive bladder and cystitis | |
| CN113274384A (en) | Application of oryzaol in preparation of medicine for preventing and treating ulcerative colitis and medicine thereof | |
| JP6642892B2 (en) | Drugs for pulmonary fibrosis including dimethylamino Micheliolide | |
| US20180353540A1 (en) | Pharmaceutical composition for treating leukemia and preparation method thereof | |
| CN113456636A (en) | Application of flufenidone in preparation of acute liver injury medicine | |
| WO2020211009A1 (en) | Use of extract from rabbit skin inflamed by vaccinia virus in treating hematopoietic system damage | |
| EP2606883B1 (en) | Uses of n-Butylidenephthalide in Treating a Liver Injury and Improving Liver Function | |
| CN105943595B (en) | Medicine for treating hand-foot syndrome caused by chemotherapy and hand-foot skin reaction caused by targeted therapy and preparation method thereof | |
| CN113476447A (en) | Application of meflonizone in preparation of acute liver injury medicine | |
| DE60020442T2 (en) | Treatment of renal cell carcinoma | |
| CN107308121A (en) | The therapeutic agent of liver regeneration | |
| CN1296087C (en) | Compound capsule for treating apoplexy involving the meridians of wind phlegm stasis blockage syndrome type and preparation process thereof | |
| CN109303792A (en) | Purposes of the pill of Eight Treasures in the drug of preparation prevention and treatment acute hepatic failure | |
| US20160303189A1 (en) | Applications of Recombined Ganoderma Lucidum Immunoregulation Protein in Preparing Drugs for Treating Tissue Fibrosis | |
| CN107281177B (en) | Method for promoting homing and engraftment of hematopoietic stem cells | |
| CN111494602B (en) | Composition for treating acute pancreatitis and application thereof | |
| CN115531459B (en) | Application of Jingfeng particles in preparing medicament for preventing or treating myocardial infarction | |
| CN114712427B (en) | Application of peach root medicine | |
| CN115154461B (en) | Application of atractylenolide I in preparation of medicine for treating sicca syndrome | |
| CN109106917B (en) | Application of traditional Chinese medicine composition in preparation of acute liver injury medicine | |
| CN106692160A (en) | Therapeutical agent for liver regeneration | |
| CN105343094A (en) | Pharmaceutical composition resisting cancer cell migration | |
| AT511582B1 (en) | USE OF KEYHOLE-LIMPET-HEMOCYANINE OR COLD PRODUCTS THEREOF | |
| DE60020635T2 (en) | Chronic myeloid leukemia therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |